With more than 20 years’ experience as a radiation oncologist, I am committed to providing comprehensive, patient-centred care by remaining at the forefront of innovative radiation therapy practice. I am based at several Icon Cancer Centre sites including Epworth Freemasons, Epworth Richmond, Moreland, Mulgrave and Canberra. After establishing my radiation oncology career at Peter MacCallum Cancer Centre, I became director of Tattersall’s Cancer Centre in 2007 (the private arm of Peter MacCallum Cancer Centre). In 2011, I was appointed inaugural Director of Epworth Radiation Oncology. In this role I built Australia’s largest stereotactic radiation therapy service including a clinical trial institute and integrated oncology services at Epworth Freemasons. In 2016, the South West Regional Cancer Centre in Warrnambool was established under my directorship and I played an integral role in the transition of Epworth Radiation Oncology to Icon Cancer Centre.I am actively involved in education, medical leadership, research and clinical trials. I was previously a member of the Epworth Medical Advisory Committee from 2007-2016 (maximum allowed 9-year tenure). I am also the Chairman of Access Telehealth; Australia’s largest provider of free consultations to patients in rural and remote areas.I have been active in numerous clinical trials and acted as principal investigator in key studies investigating radiation therapy treatments for lung, cervix and prostate cancers. In July 2019, my world-leading study TRANSFORM was published in the International Journal of Cancer, evaluating the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. In June 2021, my PINPOINT study investigating the use of Calypso guidance beacons to reduce prostate radiation therapy side effects was published in the World Journal of Urology. Both Australian studies with the support of Epworth Medical Foundation and EJ Whitten Foundation were the world’s largest clinical trials of their kind. With Dr Andrew See, I was co-investigator on PROSPER-82, the largest trial in Australia using spacing gel to protect the rectum during prostate radiotherapy. This study confirmed that spacing gel eliminates severe bowel damage.My clinical experience covers a broad range of solid tumour malignancies, with a special interest in urological cancers, gastrointestinal cancer and metastatic cancers. My profile and interests can be found on the Icon website here: https://iconcancercentre.com.au/doctor/patrick-bowden/